- Home
- MIRA vs BDRX Comparison
MIRA vs BDRX Comparison
Compare MIRA & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- BDRX
- Stock Information
- Founded
- MIRA 2020
- BDRX 2000
- Country
- MIRA United States
- BDRX United Kingdom
- Employees
- MIRA N/A
- BDRX N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- BDRX Health Care
- Exchange
- MIRA Nasdaq
- BDRX Nasdaq
- Market Cap
- MIRA 19.5M
- BDRX 5.8M
- IPO Year
- MIRA 2023
- BDRX N/A
- Fundamental
- Price
- MIRA $1.30
- BDRX $0.87
- Analyst Decision
- MIRA Strong Buy
- BDRX
- Analyst Count
- MIRA 2
- BDRX 0
- Target Price
- MIRA $14.00
- BDRX N/A
- AVG Volume (30 Days)
- MIRA 2.4M
- BDRX 3.1M
- Earning Date
- MIRA 08-12-2025
- BDRX 04-11-2025
- Dividend Yield
- MIRA N/A
- BDRX N/A
- EPS Growth
- MIRA N/A
- BDRX N/A
- EPS
- MIRA N/A
- BDRX N/A
- Revenue
- MIRA N/A
- BDRX N/A
- Revenue This Year
- MIRA N/A
- BDRX N/A
- Revenue Next Year
- MIRA N/A
- BDRX N/A
- P/E Ratio
- MIRA N/A
- BDRX N/A
- Revenue Growth
- MIRA N/A
- BDRX N/A
- 52 Week Low
- MIRA $0.57
- BDRX $0.78
- 52 Week High
- MIRA $5.01
- BDRX $41.50
- Technical
- Relative Strength Index (RSI)
- MIRA 56.46
- BDRX 38.67
- Support Level
- MIRA $1.07
- BDRX $0.85
- Resistance Level
- MIRA $1.39
- BDRX $0.92
- Average True Range (ATR)
- MIRA 0.10
- BDRX 0.06
- MACD
- MIRA 0.00
- BDRX 0.01
- Stochastic Oscillator
- MIRA 70.78
- BDRX 32.73
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.